Cocrystal Pharma

COCP on Nasdaq. Market value $19m.

Watch this stockFree. We tell you when something changes.

Should I look at this?

Look carefully before going further

Why it could be worth it

Nothing stands out yet.

Read the warning sign in its own filings

This is not advice.

Compare with another stock

Who owns it

None of the long-term investors we follow own it. 27 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

1 investor owns more than 5%.

  • OPKO HEALTH, INC.
    at least 29.6%+15.7 pts
    (filed with 3 related holders)
    Since 4 November 2026

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 1 insider bought $300,631 of shares on the open market.

  • FROST PHILLIP MD ET AL
    Director
    Bought
    Date
    5 August 2026
    Shares
    10,000
    Price
    $0.98
    Value
    $9,816
  • FROST PHILLIP MD ET AL
    Director
    Bought
    Date
    3 August 2026
    Shares
    75,000
    Price
    $0.94
    Value
    $70,590
  • FROST PHILLIP MD ET AL
    Director
    Bought
    Date
    24 February 2026
    Shares
    20,000
    Price
    $1.00
    Value
    $20,000
  • FROST PHILLIP MD ET AL
    Director
    Bought
    Date
    6 February 2026
    Shares
    50,000
    Price
    $0.95
    Value
    $47,500
  • FROST PHILLIP MD ET AL
    Director
    Bought
    Date
    31 December 2025
    Shares
    50,000
    Price
    $0.95
    Value
    $47,500
  • FROST PHILLIP MD ET AL
    Director
    Bought
    Date
    30 December 2025
    Shares
    20,000
    Price
    $0.97
    Value
    $19,400
  • FROST PHILLIP MD ET AL
    Director
    Bought
    Date
    26 December 2025
    Shares
    40,000
    Price
    $0.97
    Value
    $38,800
  • FROST PHILLIP MD ET AL
    Director
    Bought
    Date
    24 December 2025
    Shares
    25,000
    Price
    $0.97
    Value
    $24,250
  • FROST PHILLIP MD ET AL
    Director
    Bought
    Date
    26 November 2025
    Shares
    4,000
    Price
    $0.99
    Value
    $3,975
  • FROST PHILLIP MD ET AL
    Director
    Bought
    Date
    25 November 2025
    Shares
    20,000
    Price
    $0.94
    Value
    $18,800

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

1 serious warning sign in Cocrystal Pharma’s filings.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 31 Mar 2026, plus the 10-Q filed 16 Nov 2026 and 10 later 8-Ks.

  • Doubt it can keep going

    Serious

    The company or its auditor warned it may not have enough money to last the next year.

    “These factors raise substantial doubt about the Company’s ability to continue as a going concern.”
    Show the full paragraph
    The Company’s consolidated financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses and negative operating cash flows since inception. For the nine months ended September 30, 2026, the Company recorded a net loss of approximately $ 8,907 and used approximately $ 7,152 of cash in operating activities. These factors raise substantial doubt about the Company’s ability to continue as a going concern. In addition, the Company’s independent registered public accounting firm has included an explanatory paragraph in its report on the Company’s December 31, 2025 financial statements with respect to substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to raise additional funds and implement its strategies. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

    From the 10-Q filed 16 November 2026, Part I. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.